University Of Bordeaux

At the University of Bordeaux the hematology department is advancing research on blood‑derived cancers and solid tumors, including Acute Myeloid Leukemia, high‑risk myelodysplastic syndrome, myeloid sarcoma, and bone sarcomas. Trials aim to improve survival by testing new drug combinations, refining dosing strategies, and evaluating transplant conditioning methods.

• Combination of targeted agents with standard chemotherapy
• Optimal dosing of antibody‑drug conjugates in induction therapy
• Comparative stem cell transplant conditioning regimens
• Maintenance therapy with multikinase inhibitor regorafenib

These studies reflect the site’s commitment to translating innovative treatments into better outcomes for patients with aggressive malignancies.

Research on immune‑mediated kidney disease is a priority, highlighted by a trial evaluating povetacicept in adults with Immunoglobulin A Nephropathy. The goal is to lower proteinuria and protect renal function while confirming safety.

• Assessment of proteinuria reduction
• Preservation of glomerular filtration rate
• Safety profiling of novel immunomodulators

Success could offer a new therapeutic option for patients facing progressive kidney damage due to immune dysregulation.

The site is conducting pioneering gene‑therapy studies for rare inherited conditions such as Duchenne Muscular Dystrophy and primary mitochondrial disease. Early phases focus on establishing a safe dose of microdystrophin, followed by efficacy assessments and long‑term safety monitoring.

• Dose‑finding for microdystrophin gene delivery
• Comparative efficacy versus placebo in ambulatory patients
• Extended safety evaluation over 48 weeks

These investigations aim to transform the therapeutic landscape for children and adults living with genetic muscle and metabolic disorders.

While current oncology‑focused trials dominate the portfolio, the department remains prepared to expand into female reproductive health research, leveraging its expertise in immunology and genetics.

• Potential studies on autoimmune renal involvement in pregnancy
• Exploration of targeted therapies for gynecologic malignancies

Future initiatives may integrate the site’s strong translational capabilities to address unmet needs in women’s health.

The hematology unit’s focus on blood‑related malignancies creates opportunities to investigate male urogenital conditions that intersect with hematologic pathways, such as testicular involvement in leukemia.

• Investigating hematologic biomarkers in male reproductive cancers
• Assessing impact of systemic therapies on fertility parameters

Collaborative projects are anticipated to broaden the scope of male urogenital disease research at the site.

Metabolic dysfunction is a recurring theme across several trials, notably those addressing mitochondrial disease and the metabolic side effects of intensive chemotherapy for leukemia.

• Evaluation of metabolic safety in gene‑therapy recipients
• Monitoring energy metabolism during high‑dose cytarabine regimens
• Long‑term metabolic outcomes after stem cell transplantation

By integrating metabolic assessments, the University of Bordeaux seeks to optimize therapeutic tolerability and patient quality of life.